Heliyon
Volume 6, Issue 11, November 2020, e05389
Journal home page for Heliyon

Research article
Differentiation of endogenous erythropoietin and exogenous ESAs by Western blotting

https://doi.org/10.1016/j.heliyon.2020.e05389Get rights and content
Under a Creative Commons license
open access

Abstract

Doping tests for the illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. We developed a new Western blotting method to detect and distinguish endogenous erythropoietin (Epo, 35-38 kDa) and exogenous ESAs (epoetin α and β, 38-42 kDa; darbepoetin α, 47-50 kDa; epoetin β pegol, 93-110 kDa). Epo and ESAs are glycoproteins and deglycosylation using peptide-N-glycosidase F shifted all Epo and ESA bands except epoetin β pegol to 22 kDa. We cut the bands of Epo and ESAs from SDS-PAGE gels and analyzed them by Liquid Chromatography/Mass Spectrometry (LC/MS). LC/MS detected all endogenous Epo and exogenous ESAs as deglycosylated 22 kDa Epo, indicating that LC/MS analysis could confirm the presence of Epo or ESA, but could not distinguish between endogenous Epo and exogenous ESAs. We propose the following Epo doping tests: 1) detect Epo or ESAs by Western blotting of the glycosylated form; 2) increase the reliability by the band shift following deglycosylation; and 3) complete confirmation of Epo or ESA by LC/MS analysis using cut gels. One of the advantages of our method is that pre-purification of samples for Epo is not required in our Western blotting.

Keywords

Biotechnology
Biochemistry
Molecular biology
Public health
Hematological system
Renal system
Erythropoietin
Erythropoiesis-stimulating agents
Western blotting
Liquid chromatography/mass spectrometry analysis
Doping
Endogenous
Exogenous

Cited by (0)